ISSN: 2581-5407
Global Journal of Cancer Therapy
Editorial       Open Access      Peer-Reviewed

Role of tumor heterogeneity in drug resistance

Dhruv Kumar*

Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Noida (UP), India
*Corresponding author: Dhruv Kumar, J3-Block, J3-112, Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Noida (UP), India, Tel: +91-7082436598; E-mail: dhruvbhu@gmail.com; dkumar13@amity.edu
Received: 01 July, 2017 | Accepted: 19 July, 2017 | Published: 20 July, 2017

Cite this as

Kumar D (2017) Role of tumor heterogeneity in drug resistance. Glob J Cancer Ther 3(1): 032-033. DOI: 10.17352/gjct.000020

Editorial

Cancer is a leading cause of death in men worldwide and the major cause of cancer related death is drug resistance [1,2]. In past few years, scientists have established tumor heterogeneity as a phenomenon of critical importance in the natural history of individual neoplasms and drug resistance [3-5]. The concept of tumor heterogeneity has a major impact on therapeutic approaches [6-9]. Drug resistance creates difficulty in cancer treatment and is directly linked to the tumor progression and poorer prognosis. As tumor heterogeneity is very common in almost all solid tumors, cancer therapy needs to become more personalized, selective, and specific [10-13]. Understanding the mechanisms of tumor heterogeneity and drug resistance will provide sustenance for the future development of personalized cancer medicine.

Tumor heterogeneity (intra-tumoral) has been well-known for past few decades, as it was said that a single tumor consists of many cell subpopulations [6]. The biggest challenge in tumor heterogeneity is to capture all subpopulations of a solid tumor. If tumor cell subpopulation is not proficiently captured, drug-resistant subpopulations will sporadically emerge [14-16]. Some biomedical techniques (eg. Single-Cell Sequencing, Micromanipulation, Laser-Capture Microdissection, Flow Cytometry Using Fluorescence-Activated Cell Sorting, Whole Genome Amplification, Multi-Regional Sequencing Studies etc.) can be used to detect mutational heterogeneity in solid tumor and to provide personalized therapy [17-19].

In 2012, Gerlinger et al., published an article “Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing” in New England Journal of Medicine. In this article, Gerlinger et al. demonstrated that intratumor heterogeneity can contribute to drug resistance which leads to the treatment failure in renal-cell carcinoma [6]. Recently, our group for the first time demonstrated the difference in mutational heterogeneity varying by subsite in Head and neck squamous cell carcinoma (HNSCC). We demonstrated that Larynx and FOM tumors are more heterogeneous than oral tongue tumor [20,21]. The heterogeneity within tumor specimens may adopt resistance to the standard treatment protocols. These kinds of studies on tumor heterogeneity are relevant to the researchers and clinicians in developing personalized cancer therapy based on identification of specific mutations in tumor samples.

  1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. (2015) The Global Burden of Cancer 2013. JAMA Oncol 1: 505-527. Link: https://goo.gl/jL4ZUy .
  2. Cherdyntseva NV, Litviakov NV, Denisov EV, Gervas PA, Cherdyntsev ES (2017) Circulating tumor cells in breast cancer: Functional heterogeneity, pathogenetic and clinical aspects. Exp Oncol 39: 2–11. Link: https://goo.gl/xkSLLZ
  3. Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4: 244–257. Link: https://goo.gl/j9Fisp
  4. Meacham CE, Morrison SJ (2013) Tumour heterogeneity and cancer cell plasticity. Nature 501: 328–337. Link: https://goo.gl/TRmVZQ
  5. Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108: 479–485. Link: https://goo.gl/bxAUqW
  6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892. Link: https://goo.gl/gXghwm
  7. McGranahan N, Swanton C (2015) Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27: 15–26. Link: https://goo.gl/rmLcAY
  8. Singh AK, Arya RK, Maheshwari S, Singh A, Meena S, et al. (2015) Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance. Int J Cancer 136: 1991-2000. Link: https://goo.gl/Kbm6fd
  9. Lovly CM, Salama AKS, Salgia R (2016) Tumor Heterogeneity and Therapeutic Resistance. ASCO Eductional B 585-593. Link:  https://goo.gl/b6nUXi
  10. Nishino M, Jagannathan JP, Krajewski KM, O’Regan K, Hatabu H, et al. (2012) Personalized tumor response assessment in the era of molecular medicine: Cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. Am J Roentgenol 198: 737-745. Link: https://goo.gl/BCpwUz
  11. Onstenk W, Gratama JW, Foekens JA, Sleijfer S (2013) Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev 39: 691-700. Link: https://goo.gl/5GBz3t
  12. Blankenstein T, Leisegang M, Uckert W, Schreiber H (2015) Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 33: 112–119. Link: https://goo.gl/UeKZnS
  13. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G (2016) Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther 157: 120–124. Link: https://goo.gl/Q3nrkn
  14. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12: 323-334. Link: https://goo.gl/7UqmBC
  15. Rybinski B, Yun K (2016) Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget 7: 72322-72342. Link: https://goo.gl/2Q8Z7K
  16. McGranahan N, Swanton C (2017) Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 168: 613–628. Link: https://goo.gl/WFuUeB
  17. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90–94. Link: https://goo.gl/FmQpTJ
  18. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344: 1396–1401. Link: https://goo.gl/3RxzDR
  19. Schmidt F, Efferth T (2016) Tumor heterogeneity, single-cell sequencing, and drug resistance. Pharmaceuticals 9: 33. Link: https://goo.gl/uywvMi
  20. Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7: 27185-27198. Link: https://goo.gl/BZoP2t
  21. Nicholas Navin, Jude Kendall, Jennifer Troge, Peter Andrews, Linda Rodgers (2011) Tumor Evolution Inferred by Single Cell Sequencing. Nature 472: 90–94. Link: https://goo.gl/eNSzff
© 2017 Kumar D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.